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Abstract 
Background  
As atrophic gastritis and intestinal metaplasia due to Helicobacter pylori have been 
considered risk factors for gastric cancer, it is important to assess their severity. In 
the West, the operative link for gastritis assessment (OLGA) and operative link for 
gastric intestinal metaplasia assessment (OLGIM) staging systems based on biopsy 
have been widely adopted. In Japan, however, narrow-band imaging (NBI)-magnifying 
endoscopic diagnosis of gastric mucosal inflammation, atrophy, and intestinal 
metaplasia has been reported to be fairly accurate. Therefore, we investigated the 
practicality of NBI-magnifying endoscopy (NBI-ME) for gastritis staging.  
Methods 
We enrolled 55 patients, in whom NBI-ME was used to score the lesser curvature of 
the antrum (antrum) and the lesser curvature of the lower body (corpus). The 
NBI-ME score classification was established from images obtained beforehand, and 
then biopsy specimens taken from the observed areas were scored according to 
histological findings. The NBI-ME and histology scores were then compared. 
Furthermore, we assessed the NBI-ME and histology stages using a combination of 
scores for the antrum and corpus, and divided the stages into two risk groups: low and 
high. The degree to which the stage assessed by NBI-ME approximated that assessed 
by histology was then ascertained.  
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Results   
The degree of correspondence between the NBI-ME and histology scores was 69.1% 
for the antrum and 72.7% for the corpus, and that between the high- and low-risk 
groups was 89.1%.  
Conclusion  
Staging of gastritis using NBI-ME approximates that based on histology, and would 
be a practical alternative to the latter.  
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Introduction  
Atrophic gastritis and intestinal metaplasia associated with Helicobacter pylori are 
well known risk factors for gastric cancer1)2).  In the West, the OLGA (Operative Link 
for Gastritis Assessment) 3)4) and OLGIM (Operative Link for Gastric Intestinal 
Metaplasia assessment) staging systems5) have become widely used. Both systems 
assess the risk for gastric cancer on the basis of several biopsy samples taken from the 
antrum and corpus. The OLGA staging system is based on the severity and 
topography of atrophy, whereas the OLGIM staging system is based on the severity 
and topography of intestinal metaplasia3)4)5).  In Japan, on the other hand, 
narrow-band imaging (NBI)-magnifying endoscopic diagnosis of inflammation, 
atrophy, and intestinal metaplasia of the gastric mucosa has been reported to be 
fairly accurate6-10).  If the staging of gastritis based on NBI-magnifying endoscopy 
were to approximate that based on histology of biopsy specimens, it would be as 
practical as optical biopsy and reduce the work burden of endoscopists, as well as 
medical costs and procedure time.  
The present investigation was designed to determine whether gastritis staging by 
NBI-magnifying endoscopy is able to approximate that based on biopsy specimens. 
The main aim of this study was to investigate the degree of correspondence between 
the scores obtained by NBI-magnifying endoscopy and those obtained by biopsy.  
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Methods 
Study design and setting  
This was a cross-sectional study performed at Niigata Prefectural Yoshida 
Hospital between February and June 2014. This study protocol was approved by the 
institutional ethics committee.  
Participants  
We enrolled 55 patients from whom two endoscopists (AS and KY) were able to obtain 
informed consent in the outpatient department and were not using antithrombotic 
agents. Other patients who underwent gastric endoscopic examination were not 
enrolled. The patients had undergone endoscopic examinations for surveillance of 
gastric cancer with atrophic gastritis (n=16), follow-up for early gastric cancer after 
endoscopic submucosal dissection (ESD) (n=22), close examination of early gastric 
cancer before ESD (n=2), or health screening (n=15). The patients’ primary diseases 
were gastric cancer (n=24), peptic ulcer (n=13), or other diseases (n=18). Patients with 
autoimmune gastritis, previous gastrectomy, or severe hepatorenal dysfunction were 
excluded.  
 Forty-eight patients had been examined for H. pylori, and 7 had not. The presence of 
H. pylori infection was determined by at least one of the following methods: the 
13C-urea breath test (UBIT, Otsuka, Tokushima, Japan), the H. pylori stool antigen 
test (Premier Platinum HpSA; Meridian, Cincinnati, OH, USA), the serum 
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immunoglobulin (Ig) G antibody test (E-plate, Eiken, Tokyo, Japan), and biopsy 
culture. Fourteen patients were H. pylori-positive and 34 were negative. Among the 
patients who were H. pylori-negative, 28 had undergone H. pylori eradication. All of 
the remaining 6 H. pylori-negative patients had atrophic gastritis. Therefore we 
considered that H. pylori infection had resolved naturally in some of the latter 
patients (Table 1).  
Endoscopic procedures  
The instruments used in the present study were a magnifying videoendoscope and an 
electronic endoscopic system (GIF-H260Z and EVIS LUCERA Spectum; Olympus 
Medical Systems, Tokyo, Japan). All of the endoscopic examinations were performed 
by two expert endoscopists (AS and KY), who observed the lesser curvature of the 
antrum (2 cm from the pyloric ring measured using a visual scale) and the lesser 
curvature of the lower body (4 cm from the angle measured using a visual scale) by 
NBI-magnifying endoscopy. The dominant mucosal patterns in each of the two areas 
were chosen, and photographs of them were taken after thorough observation for 
detection of any lesions. Using biopsy forceps, one biopsy sample was then taken from 
each of these two areas that had been photographed. The NBI-magnifying endoscopy 
score classification was based on established magnifying endoscopy criteria for 
gastritis6-10) NBI-magnifying endoscopic scoring was performed by one endoscopist, 
and then later another endoscopist performed scoring on the basis of the pictures 
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obtained. The concordance of the scores was then confirmed. If the opinions of the 
endoscopists differed, a final judgment was arrived at by consensus following 
discussion of each individual case.  
 
NBI-magnifying endoscopy score  
Antrum  
NBI-magnifying endoscopy scores for the lesser curvature of the antrum were 
classified into four grades, as detailed below, according to the severity of intestinal 
metaplasia based on the OLGIM staging system. We diagnosed mucosa showing at 
least one of either a light blue crest (LBC) 11) or a white opaque substance (WOS) 12)13) 
(Figure 1) by NBI-magnifying endoscopy as intestinal metaplasia. LBC indicates a 
fine, blue-white line on the crests of the epithelial surface and gyri11), whereas WOS 
indicates a white opaque substance appearing on part of the surface 12)13). Both have 
been reported to be strongly related to intestinal metaplasia11)12)13).  
Score 0: Neither LBC nor WOS evident in the picture; score 1: LBC and/or WOS 
visible in less than one third of the picture; score 2: LBC and/or WOS visible in one 
third or more and less than half of the picture; score 3: LBC and/or WOS visible in 
half or more of the picture (Figure 2A).  
Corpus  
NBI-magnifying endoscopy scores for the lesser curvature of the lower body were 
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classified into the following four grades according to the severity of atrophy and 
intestinal metaplasia based on a combination of the OLGA and OLGIM staging 
systems. 
Score 0: A mucosal pattern consisting of round pits, indicating normal oxyntic glands 
without atrophy6-10); score 1: A mucosal pattern consisting of oval or slit-like pits, 
indicating non-metaplastic atrophy of oxyntic glands6-10); score 2: A tubular or 
granular mucosal pattern without LBC and WOS, indicating pseudopyloric gland 
metaplasia6-10); score 3: A tubular or granular mucosal pattern with LBC or WOS, 
indicating intestinal metaplasia with/without pseudopyloric gland metaplasia6-13) 
(Figure 2B).  
Histological score   
The biopsy samples were fixed in formalin and labeled according to their topographic 
site (antrum or corpus). They were adequately separated and distinguished during 
the paraffin-embedding procedure so that the identity of each was retained. Histologic 
sections were then obtained from each paraffin block and stained with hematoxylin 
and eosin. Histological scoring was performed by an expert pathologist (SN), blinded 
to any clinical information. In order to investigate the degree of correspondence 
between the scores obtained by NBI-magnifying endoscopy and those obtained by 
biopsy, histological scoring was performed using a histology-based system that 
incorporated the combined OLGA and OLGIM staging systems, which differed 
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slightly from the original ones.  
Antrum  
Histological scores for the lesser curvature of the antrum were classified into the 
following four grades according to the severity of intestinal metaplasia based on the 
OLGIM staging system. Score 0: No intestinal metaplasia in the biopsy specimen; 
score 1: Intestinal metaplasia in less than one third of the biopsy specimen; score 2: 
Intestinal metaplasia in one third or more and less than half of the biopsy specimen; 
score 3: Intestinal metaplasia in half or more of the biopsy specimen (Figure 3A).  
Corpus  
Histological scores for the lesser curvature of the lower body were classified into the 
following four grades according to the severity of atrophy and intestinal metaplasia 
based on the combined OLGA and OLGIM staging systems.  
Score 0: Normal oxyntic glands without atrophy; score 1: Non-metaplastic atrophy in 
oxyntic glands; score 2: Pseudopyloric gland metaplasia; score 3: Intestinal 
metaplasia with/without pseudopyloric gland metaplasia (Figure 3B).  
Evaluation of the degree of correspondence between the scores obtained by 
NBI-magnifying endoscopy and those obtained from biopsy specimens 
We investigated the distribution of the scores obtained by NBI-magnifying endoscopy 
and those obtained from biopsy specimens in the antrum and corpus, and also 
assessed the degree of correspondence between them.  
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Evaluation of the degree of correspondence between low- and high-risk groups 
determined by NBI-magnifying endoscopy and from biopsy specimens 
We tabulated the scores obtained by NBI-magnifying endoscopy and from biopsy 
specimens based on both the OLGA and OLGIM staging systems (Figure 4) and 
obtained the gastritis stages determined using both approaches. We then divided the 
stages into two groups – low risk (Stages 0, I, and II) and high risk (Stages III and IV) 
– and assessed the degree of correspondence between NBI-magnifying endoscopy and 
biopsy in each group.  
Distribution of gastritis stages in patients with gastric cancer determined by 
NBI-magnifying endoscopy and biopsy  
We assessed the distribution of gastritis stages in patients with gastric cancer, peptic 
ulcer and other diseases, and then evaluated whether the cluster of gastric cancer 
patients in the high risk group (stage III and IV) determined by NBI-magnifying 
endoscopy was similar to that determined on the basis of histology.  
 
Results  
Table 2 shows the distribution of the scores for the antrum determined by 
NBI-magnifying endoscopy and by histological examination of biopsy specimens. The 
overall rate of correspondence between the scores obtained by NBI-magnifying 
endoscopy and by histology was 69.1% (Table 2). Table 3 shows the distribution of the 
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corresponding scores for the corpus. The overall rate of correspondence between these 
scores was 72.7% (Table 3). Table 4 shows the distribution of the stages determined 
according to the scores obtained by NBI-magnifying endoscopy and histology. The 
stages were divided into two groups - low risk (Stages 0, I, and II) and high risk 
(Stages III and IV) - and the degree of correspondence between the groups determined 
on the basis of NBI-magnifying endoscopy and histology was 89.1% (49/55) (Table 5). 
The distribution of gastritis stages among 55 patients with gastric cancer, peptic ulcer 
and other diseases is shown in Table 6. Among the patients with gastric cancer, 75.0% 
(18/24) were clustered in the high-risk group (stages III and IV) on the basis of 
NBI-magnifying endoscopy whereas 79.2% (19/24) were so clustered on the basis of 
histology (Table 6).  
 
Discussion  
The updated Sydney System was drawn up mainly for diagnosis of H. 
pylori-associated gastritis, and is a quantitative scoring system based on five 
parameters evident in five biopsy samples: atrophy, intestinal metaplasia, neutrophils, 
mononuclear cells and H. pylori 14). Recently in the West, the OLGA3)4) and OLGIM5) 
staging systems based on the updated Sydney System have become widely used. The 
OLGA staging system is a histological measure of the severity and topography of 
atrophy, whereas the OLGIM staging system is based on the severity and topography 
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of intestinal metaplasia. Using these systems, determination of cases with a high risk 
of gastric cancer based on biopsy samples has been attempted5)15)16). Rugge et al.15) 
reported that in stages 0, I and II, no neoplastic lesions were detected, as they were 
all clustered in stages III and IV. In Japan, however, due to the aging of the 
population, there has been an increase in the number of patients taking 
antithrombotic agents, and therefore many elderly patients have a risk of bleeding if 
stomach biopsy is attempted. On the other hand, withdrawal of antithrombotic agents 
to avoid biopsy-related bleeding may lead to thrombosis, which can be a reason for 
medical malpractice litigation. Under these circumstances, taking several biopsy 
specimens for gastritis staging tends to be avoided in Japan. Furthermore, this 
approach for gastritis staging imposes a considerable burden on endoscopists, and 
substantially increases medical costs and procedure time.  
By contrast, we have reported an imaging diagnostic system for H. pylori-negative 
normal stomach and H. pylori-associated gastritis using NBI-magnifying endoscopy 
6-10). This system was established by comparing NBI-magnifying endoscopy findings 
with histological findings. We have diagnosed atrophy and intestinal metaplasia of 
the gastric mucosa using this NBI-magnifying endoscopy system and have recognized 
that the findings approximate those of histology6-12). It would be very useful if this 
imaging diagnostic system could be used for gastritis staging instead of biopsy 
histology, as it would eliminate bleeding risk, reduce the burden on endoscopists, and 
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help to reduce medical costs and procedure time. In the present study, therefore, we 
attempted to evaluate whether gastritis staging based on the OLGA and OLGIM 
staging systems using NBI-magnifying endoscopy is equivalent to that determined by 
histology.   
First, we determined the scores based on histological findings in the antrum and 
corpus, and then decided the scores obtained by NBI-magnifying endoscopy 
corresponding to each histological score. We carried out NBI-magnifying endoscopic 
observation and took biopsy specimens from the lesser curvature of the antrum and 
corpus of 55 patients. We then obtained the scores based on NBI-magnifying 
endoscopy and biopsy histology and investigated the degree of correspondence 
between them. This revealed a score correspondence rate of 72.7% for the corpus and 
69.1% for the antrum. The rates of correspondence between the scores based on 
NBI-magnifying endoscopy and those based on biopsy histology were higher for scores 
of 0 and 3 than for scores of 1 and 2. This suggested that normal oxyntic glands 
without atrophy, mucosa without intestinal metaplasia, and mucosa with extensive 
intestinal metaplasia would be easy to diagnose by NBI-magnifying endoscopy. The 
stages of the 55 patients were then decided according to the scores obtained by 
NBI-magnifying endoscopy and histology, and divided into two groups: low risk 
(stages 0, I, II) and high risk (stages III, IV). The degree of correspondence between 
NBI-magnifying endoscopy and histology for the two groups was 89.1%.  
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In the antrum, we investigated the severity of intestinal metaplasia according to the 
OLGIM staging system because no methods for diagnosis of pyloric gland atrophy by 
NBI-magnifying endoscopy have been reported previously. On the other hand, the 
presence of oxyntic gland atrophy in the corpus revealed by NBI-magnifying 
endoscopy has already been reported6-10). Therefore, for the corpus, we decided to 
determine the severity of atrophy and intestinal metaplasia with reference to the 
OLGA and OLGIM staging systems. Only patients from whom two endoscopists (AS 
and KY) could obtain informed consent in the outpatient department were enrolled in 
this study. Other patients who underwent gastric endoscopic examination were not 
enrolled. Therefore, the number of patients examined in this study was small. 
Accordingly, it will be necessary to investigate more patients in the future, and to 
validate this new combination of criteria.  
We investigated only two parts of the stomach, the antrum and lower corpus, because 
gastritis staging using biopsy specimens has not spread and tends to be avoided in 
Japan, and for this reason assessment of gastritis by taking several biopsy specimens 
was not approved by our institutional ethics committee.   
This was primarily a pilot study to investigate whether or not gastritis staging by 
NBI-magnifying endoscopy would be feasible and approximate the results of histology. 
We considered that the results were assessed fairly. In order to improve the accuracy 
of gastritis staging using NBI-magnifying endoscopy and make it universal, we think 
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that it should be investigated at multiple institutions and its weak points clarified.  
However, we consider that it is feasible to clarify the overall distribution of mucosal 
atrophy and intestinal metaplasia and make our approach more reproducible by 
observation of more areas by NBI-magnifying endoscopy. 
In conclusion, staging of gastritis using NBI-magnifying endoscopy is able to 
approximate that determined by histology, and is expected to be a practical approach 
that can replace staging based on the histology of biopsy specimens.  
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Figure legends  
Figure 1 
Left: NBI-magnifying endoscopic features of the light blue crest (LBC). The LBC 
appears as a fine, blue-white line on the crests of the epithelial surface and gyri.  
Right: NBI-magnifying endoscopic features of the white opaque substance (WOS). The 
WOS appears as a white opaque substance on the surface.  
Figure 2A  
Images of NBI-magnifying endoscopy in the antrum.  
LBC: light blue crest, WOS: white opaque substance 
Figure 2B  
Images of NBI-magnifying endoscopy in the corpus.  
LBC: light blue crest, WOS: white opaque substance 
Figure 3A  
Histological appearance of biopsy specimens from the antrum.  
IM: intestinal metaplasia  
Figure 3B  
Histological appearance of biopsy specimens from the corpus.   
Figure 4 
Table of gastric staging for NBI-magnifying endoscopy and histology used in this 
study, based on a combination of the OLGA and OLGIM staging systems.  
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IM: intestinal metaplasia  
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Table 1. H. pylori status of the 55 patients. 
 
H. pylori positive                  14/55  
 
H. pylori negative                 34/55 
                 
After H. pylori eradication therapy     28/34 
      
Resolved naturally                    6/34 
 
Unknown                         7/55 
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Table 2. Distribution of scores obtained by NBI-magnifying endoscopy and by 
histology of biopsy specimens for the antrum. 
 
                                          NBI-ME score  
                           0            1            2            3 
                            (25 cases)       (9 cases)      (5 cases)      (16 cases) 
 
                  0          18             2             0             0 
 
Histological     1           5             3             0             2 
   score 
                  2           1             0             3             0 
 
                  3           1             4             2            14 
 
      Correspondence of NBI-ME score to histological score, 69.1% (38/55) 
 
NBI-ME: NBI-magnifying endoscopy 
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Table 3. Distribution of scores obtained by NBI-magnifying endoscopy and by 
histology of biopsy specimens for the corpus. 
 
                                          NBI-ME score  
                           0            1            2            3 
                            (10 cases)       (17 cases)      (4 cases)      (24 cases) 
 
                  0          10             4             0             0 
 
Histological     1           0             7             1             0 
   score 
                  2           0             2             0             1 
 
                  3           0             4             3            23 
 
  Correspondence of NBI-ME score to histological score, 72.7% (40/55). 
 
NBI-ME: NBI-magnifying endoscopy 
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Table 4. Distribution of stages determined by NBI-magnifying endoscopy and histology 
of biopsy specimens.  
  
                                       Stage by NBI-ME 
                         Stage 0    Stage I    Stage II    Stage III    Stage IV 
                         (9 cases)  (17 cases)   (4 cases)    (6 cases)   (19 cases) 
 
            Stage 0        7           3          0          0          0 
   
 Stage I        2           7          0           0          0 
Stage by    
histology   Stage II       0           3          3           1          0 
         
            Stage III      0           3          0           1          3 
  
            Stage IV      0           1          1           4          16 
  
 
NBI-ME: NBI-magnifying endoscopy 
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Table 5. Distribution of groups determined according to the scores of NBI-magnifying 
endoscopy and histological score. 
. 
 
                                          Group by NBI-ME  
                                   Low risk                High risk 
                                                    (30 cases)               (25 cases) 
                   
Low risk             25                       1 
          
Group by      
Histological score 
                     High risk              5                       24 
                 
 
 Correspondence of group determined by NBI-ME to that determined by 
histology, 89.1% (49/55). 
 
Low risk: stage 0, stage I and stage II 
High risk: stage III and stage IV 
 
NBI-ME: NBI-magnifying endoscopy 
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Table 6. Case distribution of gastritis staging in 55 patients with gastric cancer, peptic 
ulcer and other diseases by NBI-magnifying endoscopy and histology. 
 
Stage by NBI-ME 
                  Stage 0     Stage I     Stage II     Stage III     Stage IV 
Gastric cancer       1           3           2            4            14 
  (n=24)          (4.2%)       (12.5%)     (8.3%)       (16.7%)      (58.3%) 
Peptic ulcer         5            5          0            0             3 
  (n=13)          (38.5%)      (38.5%)     (0%)         (0%)        (23.1%) 
Others            3           9           2            2            2  
  (n=18)          (16.7%)      (50.0%)     (11.1%)      (11.1%)      (11.1%) 
 
 
 
Stage by histology 
                 Stage 0     Stage I     Stage II     Stage III     Stage IV 
Gastric cancer       0          3            2           2            17 
  (n=24)           (0%)      (12.5%)       (8.3%)      (8.3%)       (70.8%)                                              
Peptic ulcer          4          2           1           2             4 
(n=13)          (30.8%)    (15.4%)       (7.7%)      (15.4%)      (30.8%) 
Others            6          4            4           3             1 
(n=18)          (33.3%)    (22.2%)      (22.2%)      (16.7%)       (5.6%)  
 
 
NBI-ME: NBI-magnifying endoscopy 
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